| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A011801 | This study is for patients who are HER2 (+) and have undergone surgery to remove the cancer and have residual disease. This study looks at adding Tucatinib to standard of care treatment. | Cancer | Breast |
| A071701 | This study is for patients who brain metastasis. Patients must have an actionable alteration in NTRK, ROS1, KRAS G12C or CDK pathway or P13K. | Cancer | Brain Mets |
| A072201 | This study if for patients with recurrent glioblastomas. It is looking at standard of care treatment (Lomustine) vs Anti-LAG-3 and Anti-PD-L1 Blockade. | Cancer | Glioblastoma |
| NRG GU013 | This study is for patients with high risk prostate cancer. PSA must be >20 ng/ml. Patient must have a Gleason score of 8-10. Patient cannot have metastatic disease outside of pelvic lymph nodes. No prior radiation or androgen deprivation therapy allowed. | Cancer | Prostate |
| NRG-GU011 | The purpose of this study is to look at adding Androgen deprivation therapy in patients with prostate cancer with only a few areas of metastasis. You must have had prior curative intent treatment to the prostate. | Cancer | Prostate |
| RTOG 1216 | This study is for patients with squamous cell cancer of the head and neck. It looks at after surgery adding radiation to the standard of care chemotherapy to treat the cancer. | Cancer | Head & Neck |
| S1900G (LUNGMAP substudy) | The purpose of this study is to determine if adding ramucirumab in combination with capmatinib and osimertinib is effective in treating patients with Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900J (LUNGMAP substudy) | The purpose of this study is see if Amivanatamab is effective in treating patients with MET-Amplification Positive Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900K (LUNGMAP substudy) | The purpose of this study is to determine if the use of Tepotinib with or without Ramucirumab is effective in patients with MET Exon 14 skipping positive stage 4 or recurrent non-small cell lung cancer (NSCLC).(LUNGMAP sub-study) | Cancer | Metastatic Non-Small Cell Lung |
| S2312 | This study is for patients with metastatic prostate cancer. It looks at using Cabazitaxel with or without carboplatin in patients with castrate-resistant prostate cancer. | Cancer | Prostate |
| URCC 19075 | This study is for patients who have chemotherapy induced peripherial neuropathy. It looks at using exercise to improve neuropathy symptoms. Patients must be receiving or have received neurotoxic chemo in the last 9 months. Patients must not have limitations to moderate exercise. | Cancer | All tumor types |
| S2303 | This study is for patients who have progressed on standard of care treatment for gastric or esophageal cancer. The study looks at adding Nivolumab to 2nd line treatment to see if it improves outcomes. | Cancer | Gastric or Esophageal |
| Basic | The purpose of this study is to test if different mobile or wearable devices can measure how much time a person's heart is in atrial fibrillation over a period of 4 months. | Heart & Vascular | Atrial Fibrillation |
| Picasso | The study is trying to assess the safety and efficacy of fixing the narrowing in your carotid artery using a stent versus using a balloon or suction method when performed at the same time as the mechanical thrombectomy. | Neurosciences | Stroke |
| EA5221 | The purpose of this study is to determine in the older adult population if immunotherapy alone is better than immunotherapy + chemotherapy. Patients must be 70+ with diagnosis of Non-Small Cell Lung Cancer. | Cancer | Non-Small Cell Lung Cancer |
| NRG BN011 | The purpose of this study is to determined if combination therapy radiation is more effective than single agent therapy with radiation. Patients must be diagnosed with a Methylated MGMT promoter Gliblastoma. | Cancer | Gliblastoma |
| NRG CC011 | This study is for patients with stage 1-3 breast cancer. Patient must be > 6 months to 5 years out from treatment and experiencing symptoms of brain fog. The study using cognitive training to try to improve brain fog symptoms. | Cancer | Breast |
| COMPaCT | This study is for patients who have a diagnosis and medical condition that requires a cholecystectomy. A cholecystectomy is the surgical removal of the gallbladder, which stores bile for use in digestion. The purpose of this study is to collect information about the outcome of the surgery, as well as the patient’s pain and quality of life after laparoscopic or robotic-assisted cholecystectomy, in order to provide more information to the surgical community. | Gastroenterology | Surgery |
| Librexia ACS | The purpose of this study is to see if an experimental drug, called milvexian is safe, effective and useful in reducing risk of developing blood clots, stroke, or another heart attack among subjects with a recent heart attack or angina (chest pain) episode. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA). | Heart & Vascular | Atrial Fibrillation |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EA8211 | This study is for patients with renal cell cancer who have a total of 2-5 metastatic lesions. The study is looking at using radiation to the metastatic sites in combination with chemotherapy. | Cancer | Metastatic Renal Cell |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| SOUL Music | This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants. | Surgery | Urinary Stone Disease |
| EAY191-E5 | This study is for patients who have a KRAS G12C mutation and advanced/metastatic solid tumors. Your cancer must have progressed on standard of care therapy. You cannot have colorectal cancer or non-small cell lung cancer. | Cancer | Solid Tumors |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. | Cancer | Solid Tumors |
| Intuitive Surgical Ureter | The purpose of this study is to investigate whether the study drug may allow the surgeon to better see the ureters when using the da Vinci Surgical System for gynecological surgery. | Surgery | Gynecology |
| NRG-BR009 | The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. | Cancer | Breast |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.